CytoSorbents Corp (CTSO) - Product Pipeline Analysis, 2023 Update

Summary


CytoSorbents Corp (CytoSorbents) is a medical device company that focuses on treating life-threatening conditions in the ICU and cardiac surgery using blood purification. It offers products such as CytoSorb, HemoDefend, ECOS-300CY, DrugSorb-ATR and VetResQ. The company's flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriously ill patients by reducing excessive cytokines and bacterial toxins. CytoSorbents offers DrugSorb, a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood, VetResQ, a blood purification adsorber, to support and treat excessive inflammation and toxic injury in animals. The company offers its products through a network of distributors across Europe, the Middle East and Asia Pacific. CytoSorbents is headquartered in Monmouth Junction, New Jersey, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company CytoSorbents Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company


CytoSorbents Corp Company Overview
CytoSorbents Corp Company Snapshot
CytoSorbents Corp Pipeline Products and Ongoing Clinical Trials Overview
CytoSorbents Corp – Pipeline Analysis Overview
CytoSorbents Corp - Key Facts
CytoSorbents Corp - Major Products and Services
CytoSorbents Corp Pipeline Products by Development Stage
CytoSorbents Corp Ongoing Clinical Trials by Trial Status
CytoSorbents Corp Pipeline Products Overview
BetaSorb
BetaSorb Product Overview
ContrastSorb
ContrastSorb Product Overview
CST 301
CST 301 Product Overview
CytoSorb
CytoSorb Product Overview
CytoSorb Clinical Trial
CytoSorb-XL
CytoSorb-XL Product Overview
DrugSorb-ATR
DrugSorb-ATR Product Overview
HemoDefend BGA
HemoDefend BGA Product Overview
HemoDefend RBC
HemoDefend RBC Product Overview
K+ontrol
K+ontrol Product Overview
CytoSorbents Corp - Key Competitors
CytoSorbents Corp - Key Employees
CytoSorbents Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
CytoSorbents Corp, Recent Developments
Jan 17, 2024: Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb Intraoperatively in Heart Transplant Patients
Dec 28, 2023: Cytosorbents Provides Update on the Star-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
Sep 19, 2023: CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
Sep 01, 2023: CytoSorbents receives expanded registration from ANVISA for CytoSorb
Aug 14, 2023: CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial
Jul 07, 2023: CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
Apr 20, 2023: CytoSorbents’ pivotal STAR-T trial reaches second key milestone with 80 patients enrolled
Mar 29, 2023: Landmark publication underscores robust ability of CytoSorb to reduce cytokine storm during systemic hyperinflammation
Mar 09, 2023: CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
Mar 07, 2023: New European “Guidelines for the Management of Severe Perioperative Bleeding” consider hemoadsorption for the first-time
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: CytoSorbents Corp Pipeline Products and Ongoing Clinical Trials Overview
Table 2: CytoSorbents Corp Pipeline Products by Equipment Type
Table 3: CytoSorbents Corp Pipeline Products by Indication
Table 4: CytoSorbents Corp, Key Facts
Table 5: CytoSorbents Corp, Major Products and Services
Table 6: CytoSorbents Corp Number of Pipeline Products by Development Stage
Table 7: CytoSorbents Corp Pipeline Products Summary by Development Stage
Table 8: CytoSorbents Corp Ongoing Clinical Trials by Trial Status
Table 9: CytoSorbents Corp Ongoing Clinical Trials Summary
Table 10: BetaSorb - Product Status
Table 11: BetaSorb - Product Description
Table 12: ContrastSorb - Product Status
Table 13: ContrastSorb - Product Description
Table 14: CST 301 - Product Status
Table 15: CST 301 - Product Description
Table 16: CytoSorb - Product Status
Table 17: CytoSorb - Product Description
Table 18: CytoSorb - A Prospective, Randomized, Multicenter, Single-blind, Controlled Study to Assess the Performance of the Cytosorb 300 ml Device for Shock Reversal in Patients with Vasoplegic Septic Shock
Table 19: CytoSorb - COOLEY- Study: Acute on Chronic Liver Failure Using the Cytosorb Device
Table 20: CytoSorb - Cytokine Adsorption in Patients with Acute-on-chronic Liver Failure (CYTOHEP) - A Single Center, Open-label, Randomized, Controlled Intervention Trial
Table 21: CytoSorb - Cytokine Filter Usage During Open Thoracoabdominal Aortic Aneurysm Repair- A Single-center Randomized Prospective Trial- Cytosorb and Its Impact on Open TAAA Repair Outcome
Table 22: CytoSorb - Cytokine Filtration in Lung Transplantation - a Randomised, Controlled, Multicentre Clinical Trial (GLUSorb)
Table 23: CytoSorb - Cytosorb Modulation of Surgical Inflammation During LVAD Insertion
Table 24: CytoSorb - CytoSorb Treatment of Critically Ill Patients Registry: International Registry on the Use of CytoSorb in the Critical Care Setting
Table 25: CytoSorb - Development and Use of a Population Pharmacokinetic Model of Amikacin and Vancomycin for the Optimization of Dosing Regimens in Critically Ill Patients on Different Modalities of Extracorporeal Hemoadsorption
Table 26: CytoSorb - ECMOsorb Trial - Impact of a VA-ECMO in Combination with CytoSorb in Critically Ill Patients with Cardiogenic Shock - A Prospective, Randomized, Blinded, Monocenter Trial
Table 27: CytoSorb - Effect of Haemoadsorption During Cardiopulmonary Bypass on Patients After Heart Transplantation
Table 28: CytoSorb - Effectivity of Extracorporeal Cytokine Adsorption (Cytosorb) as Additive Treatment of CAR-T Cell Associated Cytokine Release (CRS) Syndrome and Encephalopathy Syndrome (CRES)
Table 29: CytoSorb - Prevention of Vasoplegia with the Use of CytoSorb
Table 30: CytoSorb - Removal of Cytokines With Cytosorbents After Inflammatory Response Reaction During Cardiac Surgery and Association of Endothelial Progenitor Cells
Table 31: CytoSorb - Safe and Timely Antithrombotic Removal (STAR) Registry: International Registry on the Use of CytoSorb for Removal of Antithrombotic Agents in the Acute Hospital Setting
Table 32: CytoSorb - The Effect of the CytoSorb Filter to Remove Anticoagulants From the Circulation During Emergency Surgery for Aortic Dissection
Table 33: CytoSorb-XL - Product Status
Table 34: CytoSorb-XL - Product Description
Table 35: DrugSorb-ATR - Product Status
Table 36: DrugSorb-ATR - Product Description
Table 37: HemoDefend BGA - Product Status
Table 38: HemoDefend BGA - Product Description
Table 39: HemoDefend RBC - Product Status
Table 40: HemoDefend RBC - Product Description
Table 41: K+ontrol - Product Status
Table 42: K+ontrol - Product Description
Table 43: CytoSorbents Corp, Key Employees
Table 44: CytoSorbents Corp, Subsidiaries
Table 45: Glossary
List of Figures
Figure 1: CytoSorbents Corp Pipeline Products by Equipment Type
Figure 2: CytoSorbents Corp Pipeline Products by Development Stage
Figure 3: CytoSorbents Corp Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings